TEVA — Teva Pharmaceutical Industries Limited American Depositary Shares price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $42.61
- YTD price return
- +36.53%
- YTD total return
- +36.53%
- Market cap
- 49.7B
- Enterprise value
- 62.8B
- Shares outstanding
- 1.2B
- 52W low
- $23.61
- 52W high
- $43.34
- From 52W high
- -1.68%
- From 52W low
- +80.47%
- 52W range
- 96%$23.61–$43.34
- Beta
- 0.86
Volume
- Rel volume
- 0.90×
- 30D volume
- 6.8M
- 30D $ vol
- 278.8M
Insider trading
- Insider net 1W
- −$3.0M
- Insider net 1M
- −$3.0M
- Insider net 3M
- −$18.7M
- Insider net 1Y
- −$96.2M
Form 4 transactions by trade date, as filed; latest on file 2026-11-05.
Fundamentals
- Sales (ttm)
- 17.2B
- Sales/share
- $14.77
- EPS (ttm)
- $0.43
- FCF (ttm)
- 1.2B
- FCF/share
- $1.06
- Book value/share
- $6.84
- Net margin
- 2.94%
- ROE
- 6.34%
- ROA
- 1.26%
- Debt / equity
- 1.59×
- Current ratio
- 0.95
Growth (CAGR, ttm) · 10Y
- Sales
- +2.71%+4.10%+1.20%-2.43%
- Net income
- -28.95%n/a-6.97%+4.52%
- FCF
- +113.95%+26.67%+69.64%-8.66%
- Shares
- +1.70%+1.35%+1.13%+1.72%
Per-share growth (CAGR, ttm) · 10Y
- EPS
- -30.17%n/a-8.18%+20.49%
- Sales/share
- +0.99%+2.72%+0.07%-3.79%
- FCF/share
- +110.37%+24.99%+67.75%-9.93%
- Book value/share
- +8.22%+3.42%-6.34%-14.85%
- Price
- +74.27%+67.59%+36.07%+0.57%
- Total return
- +74.27%+67.59%+36.07%+0.95%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- 98.9×
- P/OI (ttm)
- 34.6×
- Fwd P/E
- 13.4×
- P/S (ttm)
- 2.9×
- P/B (mrq)
- 6.2×
- P/FCF (ttm)
- 40.2×
- EV/EBITDA (fy)
- 25.9×
- EV/Sales (ttm)
- 3.6×
- FCF yield (ttm)
- 2.49%
- Buyback yield (realized, 1y)
- -1.70%
- Shareholder yield (realized, 1y)
- -1.70%
- Buyback yield (cash, ttm)
- 0.00%
- Shareholder yield (cash, ttm)
- 0.00%
Vs own 10Y history
- P/OI
- 80th
- P/S
- 100th
- P/B
- 100th
- P/FCF
- 90th
Bar = where today’s multiple sits in TEVA’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-06#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y n/m10Y CAGR −4.3%YoY −19.0%EPS (diluted)
5Y n/m10Y CAGR −4.0%YoY −45.9%Free cash flow
5Y CAGR +12.5%10Y CAGR −13.3%YoY −48.1%TTM: operating cash flow $1.8B, capex −$534M
Q3 2026: operating cash flow $241M, capex −$120M
Shares (diluted)
5Y +6.2%10Y +34.6%YoY +1.6%Dividend per share
5Y n/m10Y n/mNo quarters filed for this figure.
About Teva Pharmaceutical Industries ADR#
Data provided bySource: Twelve DataTeva Pharmaceutical Industries Ltd. ADR is a global pharmaceutical company focused on the development, production, and sale of medicines. Teva Pharmaceutical Industries Ltd. offers a broad portfolio that includes generic medicines, specialty branded treatments, over-the-counter products, active pharmaceutical ingredients, and contract manufacturing services. Its operations are organized across the United States, Europe, and International Markets, supporting distribution to healthcare systems, pharmacies, and patients in diverse regions. The company also provides out-licensing and other pharmaceutical services through affiliated platforms, making it an important supplier within the global drug manufacturing and distribution chain. Headquartered in Tel Aviv, Israel, Teva Pharmaceutical Industries Ltd. ADR plays a significant role in the access and supply of essential medicines across multiple therapeutic areas and market segments.
Tel Aviv-Yafo, Israel·31,173 employees·Drug Manufacturers - Specialty & Generic·tevapharm.com·As of Oct 28, 2026
Recent filings#
- Nov 5Insider sale · Sabag Mark (See "Remarks") sold 46,000 shares for $1.9M at $41.93
- Nov 4Insider sale · Bergwerk Dov (Interim Cheif Legal Officer) sold 26,260 shares for $1.1M at $41.72
- Nov 3Earnings · Earnings release — EPS $0.83 vs $0.70 est. (+18.6%); revenue $4.39B (−2% y/y) 3.0%
- Sep 18Insider sale · MIGNONE ROBERTO (Director) sold 367,600 shares for $14.4M at $39.06
- Sep 18Insider sale · Savage Brian (Interim Chief Legal Officer) sold 7,342 shares for $285K at $38.69–$39.15
ETFs holding TEVA#
4 of the 193 ETFs ChartRow carries live hold TEVA. Their positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Jul 26).
| Fund | Name | Filed weight |
|---|---|---|
| VEA | Vanguard FTSE Developed Markets ETF | 0.1% |
| VEU | Vanguard FTSE All-World ex-US ETF | 0.1% |
| VXUS | Vanguard Total International Stock ETF | 0.1% |
| VT | Vanguard Total World Stock ETF | 0.0% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +16.98% | -0.79% |
| JNJ | Johnson & Johnson | +8.42% | +1.43% |
| ABBV | AbbVie Inc. | +9.23% | +1.07% |
| MRK | Merck & Co. Inc. | +3.37% | -0.14% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +4.74% | -0.40% |
| NVS | Novartis AG | +15.46% | +0.38% |
| TMO | Thermo Fisher Scientific Inc. | +5.81% | +2.63% |
| AMGN | Amgen Inc. | +14.36% | +0.03% |
